News

November 3, 2020November 3, 2020

CAR T-Cell Therapy, MB-105, Shows Promise in Metastatic CRPC Patient in Phase 1 Trial

News

A heavily pretreated patient with metastatic castration-resistant prostate cancer (mCRPC) showed significant benefits, including a 94% decrease in the levels of the prostate-specific antigen (PSA) biomarker, one month after receiving MB-105 ... Read more

October 29, 2020October 29, 2020

FDA Clears Ezra Prostate AI, a First for Cancer Imaging

News

The U.S. Food and Drug Administration (FDA) has cleared Ezra Prostate AI, an artificial intelligence (AI) program designed to increase the efficiency with which radiologists analyze images of the prostate ... Read more

October 27, 2020October 27, 2020

New Targeted Therapy Trial Opens, Part of PC-BETS Metastatic CRPC Study

News

A trial opened to investigate CFI-400945, by Treadwell Therapeutics, as a potential oral therapy for people with metastatic castration-resistant prostate cancer (mCRPC), the company announced in a press release. It is one of ... Read more

October 22, 2020October 22, 2020

ADT Not Needed With Radiation in Favorable Intermediate-Risk PC

News

Adding four months of androgen deprivation therapy (ADT) to radiation treatment extends survival and delays metastasis in men with unfavorable intermediate-risk prostate cancer, according to a secondary analysis of a Phase ... Read more

October 20, 2020October 20, 2020

Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga, Real-world Study Finds

News

Provenge (sipuleucel-T), by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with metastatic castration-resistant prostate cancer (mCRPC) when added at any ... Read more

October 15, 2020October 15, 2020

Trial to Test Focal Laser Ablation Therapy for Localized Prostate Cancer

News

An investigator-initiated trial soon will evaluate Clinical Laserthermia Systems’ Tranberg Thermal therapy, a focal ablation therapy, for the treatment of prostate cancer patients who have up to medium-grade, localized tumors. ... Read more

October 13, 2020October 13, 2020

New AI Algorithm Can Accurately Identify, Grade Prostate Cancer

News

A new artificial intelligence (AI) algorithm has been developed that can accurately detect and grade prostate cancer, using slide images from patient core needle prostate biopsies, a study reports. The ... Read more

October 8, 2020October 8, 2020

Veru Completes Enrollment for Second Part of Phase 1/2 VERU-111 Trial

News

Veru has completed enrollment for the second portion of a Phase 1/2 study of VERU-111, its investigational therapy for men with metastatic castration-resistant prostate cancer (mCRPC) who failed to respond ... Read more

October 6, 2020October 6, 2020

Lantheus Seeks FDA Approval of PyL Prostate Cancer Imaging Agent

News

Lantheus Holdings has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of PyL, an investigational imaging agent used to locate prostate cancer lesions. The new ... Read more

October 1, 2020October 1, 2020

Relugolix Fails to Delay Castration Resistance in Advanced PC, Trial Shows

News

Relugolix, a form of hormone therapy for prostate cancer, has failed to significantly extend the time men with advanced disease live without acquiring resistance to castration medications, compared with standard-of-care ... Read more